WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 522512
Description: TG6-10-1 is a potent and selective antagonist for the prostaglandin E2 receptor subtype EP2. Systemic administration of TG6-10-1 completely recapitulates the effects of conditional ablation of cyclooxygenase-2 from principal forebrain neurons, namely reduced delayed mortality, accelerated recovery from weight loss, reduced brain inflammation, prevention of blood-brain barrier opening, and neuroprotection in the hippocampus, without modifying seizures acutely. TG6-10-1 shows low-nanomolar antagonist activity against EP2.
MedKoo Cat#: 522512
Chemical Formula: C23H23F3N2O4
Exact Mass: 448.16099
Molecular Weight: 448.44
Elemental Analysis: C, 61.60; H, 5.17; F, 12.71; N, 6.25; O, 14.27
TG6-10-1, purity > 98%, is in stock. The same day shipping out after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide). Shipping fee: from $30.00 (USA); from $45.00 (Canada); from $70.00 (international). Note: the estimated shipping out time for order > 200mg may be 2 weeks.
Synonym: TG6-10-1; TG 6-10-1; TG-6-10-1; TP6101; TP-6101; TP 6101.
IUPAC/Chemical Name: (E)-N-(2-(2-(trifluoromethyl)-1H-indol-1-yl)ethyl)-3-(3,4,5-trimethoxyphenyl)acrylamide
InChi Key: WUYOECAJFJFUFC-CMDGGOBGSA-N
InChi Code: InChI=1S/C23H23F3N2O4/c1-30-18-12-15(13-19(31-2)22(18)32-3)8-9-21(29)27-10-11-28-17-7-5-4-6-16(17)14-20(28)23(24,25)26/h4-9,12-14H,10-11H2,1-3H3,(H,27,29)/b9-8+
SMILES Code: O=C(NCCN1C(C(F)(F)F)=CC2=C1C=CC=C2)/C=C/C3=CC(OC)=C(OC)C(OC)=C3
The following data is based on the product molecular weight 448.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Rojas A, Ganesh T, Lelutiu N, Gueorguieva P, Dingledine R. Inhibition of the
prostaglandin EP2 receptor is neuroprotective and accelerates functional recovery
in a rat model of organophosphorus induced status epilepticus. Neuropharmacology.
2015 Jun;93:15-27. doi: 10.1016/j.neuropharm.2015.01.017. Epub 2015 Feb 3. PubMed
PMID: 25656476; PubMed Central PMCID: PMC4387070.
2: Jiang J, Quan Y, Ganesh T, Pouliot WA, Dudek FE, Dingledine R. Inhibition of
the prostaglandin receptor EP2 following status epilepticus reduces delayed
mortality and brain inflammation. Proc Natl Acad Sci U S A. 2013 Feb
26;110(9):3591-6. doi: 10.1073/pnas.1218498110. Epub 2013 Feb 11. PubMed PMID:
23401547; PubMed Central PMCID: PMC3587237.